Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Businessweek Archives

Bolar's Pain Is Getting Acute


In Business This Week

BOLAR'S PAIN IS GETTING ACUTE

The headaches go on at Bolar Pharmaceutical. On Aug. 27, the generic-drug manufacturer announced a $40 million settlement with SmithKline Beecham over Bolar's manufacture and sale of a generic version of SmithKline's Dyazide blood-pressure medicine.

It was only the latest in a string of costly settlements for Bolar. Earlier this year, the company agreed to pay $23.8 million to settle Dyazide-related suits brought by drug buyers and shareholders. In March, it agreed to pay $10 million in fines and pleaded guilty to federal charges of distributing adulterated and misbranded drugs and obstructing federal investigations. The company's future now is unclear. Last year, it stopped producing just about all of its products.EDITED BY PETER FINCH


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus